Status:
UNKNOWN
Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction
Lead Sponsor:
Xuzhou Central Hospital
Conditions:
Coronary Heart Disease
Eligibility:
All Genders
20-80 years
Phase:
PHASE4
Brief Summary
The investigators evaluate the effects of intracoronary and intravenous administration of nicorandil on cardiac sympathetic nerve activity and distribution in patients with acute myocardial infarction...
Detailed Description
Reperfusion injury might occur in patients with acute ST segment elevation myocardial infarction undergoing the primary percutaneous coronary intervention(P-PCI),characterized by myocardial stunning, ...
Eligibility Criteria
Inclusion
- acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;
- Age20-80,All genders
- anterior myocardial infarction
- The first myocardial infarction
- The infarct-related artery(IRA) is totally occlusive
- Blood pressure is higher than 90/60 millimeters of mercury（mmHg）
- The time from myocardial infarction onset to reach the hospital is less than 12 hs
Exclusion
- kidney dysfunction (creatinine \>2 mg/dl),
- History of previous liver disease,
- Cardiogenic shock,
- History of myocardial infarction (MI)
- History of coronary artery bypass grafting
- History of allergic response to drugs
- Severe hypovolemia
Key Trial Info
Start Date :
April 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04826497
Start Date
April 1 2021
End Date
February 1 2022
Last Update
April 1 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.